Nuveen LLC Invests $670,000 in Annexon, Inc. $ANNX

Key Points

• Nuveen LLC acquired a new stake in Annexon, Inc., purchasing 347,032 shares valued at approximately $670,000 during the first quarter.
• Analysts have varied opinions on Annexon, with Zacks Research upgrading the stock to a "hold" rating, while HC Wainwright set a price target of $14.00.
• Annexon's stock is currently priced at $2.05, with a market cap of $225.27 million, and it reported earnings of ($0.34) per share, beating analyst expectations.

Nuveen LLC acquired a new stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 347,032 shares of the company's stock, valued at approximately $670,000. Nuveen LLC owned approximately 0.32% of Annexon as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Annexon during the 4th quarter valued at approximately $59,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Annexon during the fourth quarter worth $252,000. Nuveen Asset Management LLC raised its position in shares of Annexon by 6.5% during the 4th quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company's stock valued at $13,956,000 after acquiring an additional 164,915 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Annexon during the 4th quarter valued at about $177,000. Finally, California State Teachers Retirement System lifted its stake in Annexon by 849.0% in the 4th quarter. California State Teachers Retirement System now owns 66,375 shares of the company's stock valued at $341,000 after acquiring an additional 59,381 shares in the last quarter.

Annexon Stock Up 0.2%

Shares of ANNX stock traded up $0.01 during trading hours on Monday, reaching $2.18. 632,852 shares of the stock traded hands, compared to its average volume of 1,533,207. The business has a fifty day moving average price of $2.41 and a 200 day moving average price of $2.24. The firm has a market capitalization of $239.01 million, a PE ratio of -1.69 and a beta of 1.16. Annexon, Inc. has a 1-year low of $1.28 and a 1-year high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. Research analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANNX has been the topic of several research analyst reports. Needham & Company LLC reduced their price objective on Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Annexon in a research note on Friday, August 15th. Finally, Zacks Research raised Annexon from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Annexon presently has an average rating of "Moderate Buy" and an average target price of $12.50.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.